Tag: Rachel Sachs

Health Law Professor & Institute for Public Health Faculty Scholar, Rachel Sachs discusses the role of state boards on drug affordability and what their decisions can mean for the public.

Law Professor and Institute Faculty Scholar, Rachel Sachs discusses a change in reimbursement to providers as CMS-the Centers for Medicare & Medicaid Services-works with the FDA to accelerate payment reforms.

Faculty Scholar and professor at the School of Law, Rachel Sachs discusses “PBM reform”.

Faculty Scholar, Rachel Sachs discusses data from drug extension trials, which did not show substantial effectiveness.

Law professor and Institute Faculty Scholar, Rachel Sachs, JD, speaks about drug importation and how it is not currently used for lowering prices.

The Inflation Reduction Act allows Medicare for the first time to negotiate with drug manufacturers for lower prices. Faculty Scholar, Rachel Sachs weighs in.

Because there is currently no way to change prescription premiums mid-year and save people money, law professor and Faculty Scholar, Rachel Sachs says, the high costs of drugs rejected by Medicare are unfortunately passed on to consumers.

Health law expert and Faculty Scholar Rachel Sachs discusses a new deal in congress that would fund the FDA.

Rachel Sachs JD, MPH, institute Faculty Scholar and Treiman Professor of Law at the School of Law, explains some of the cost-cutting provisions in the Inflation Reduction Act specific to Medicare in this AP article.

Check out this Bloomberg Law article featuring Rachel Sachs JD, MPH, institute Faculty Scholar, who discusses how pharmaceutical companies may begin to encourage biosimilar products to come to market to avoid negotiating drug prices with Medicare.

Institute Faculty Scholar, Rachel Sachs JD, MPH, speaks with Axios about how recent legislation, that enables Medicare to negotiate drug prices with pharmaceutical companies, may impact the development of cancer treatments.

Check out this New York Times article featuring Institute Faculty Scholar and Treiman Professor of Law at the School of Law, Rachel Sachs JD, MPH, who discusses some misunderstandings surrounding the Inflation Reduction Act.

Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs JD, MPH, discusses the recent Inflation Reduction Act that will ultimately enable Medicare to negotiate drug prices with the pharmaceutical industry.

Rachel Sachs JD, MPH, institute Faculty Scholar and Treiman Professor of Law at the School of Law, speaks with Fierce Pharma about the pharmaceutical industry’s response to the Biden administration, specifically the recent Inflation Reduction Act.

Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs JD, MPH, discusses the impact of a new bill that allows Medicare to negotiate drug prices for a select number of expensive drugs.

Rachel Sachs JD, MPH, institute faculty scholar and Treiman Professor of Law at the School of Law, discusses recent federal legislation that enables Medicare to negotiate the prices of some of the most expensive pharmaceuticals

Institute Faculty Scholar and Treiman Professor of Law at the School of Law, Rachel Sachs JD, MPH, discusses with EndpointNews possible legal avenues for PhRMA following recent federal legislation

Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs discusses the new bill that would allow Medicare to negotiate drug prices for a select number of expensive drugs.

Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs discusses the new bill that would allow Medicare to negotiate drug prices for a select number of expensive drugs

Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs discusses the new Senate bill that would allow Medicare to negotiate drug prices for a select number of very expensive drugs in this Washington Post article.

Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs, weighs in on the validity of an ad targeting Senator Joe Manchin and AARP, characterizing it as “fairly misleading”

Rachel Sachs, institute faculty scholar and Treiman Professor of Law at the School of Law, discusses with Bloomberg the potential for restrictions on medications in Missouri following the Supreme Court’s overturning of Roe v. Wade.